Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1993-11-01
1995-10-24
Jordan, Kimberly R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514423, 514929, A61K 3166, A61K 3140
Patent
active
054610397
ABSTRACT:
A method is provided for treating hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.
REFERENCES:
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
Olefsky et al, "Insulin Action and Resistance in obesity and non-insulin dependent type II diabetes mellitus," Am. J. Physiol. 1982; 243:E15-330.
Stout, R. W., "Insulin and atheroma--an update," Lancet 1987, I:1077-1079.
Ferrannini et al, "Insulin resistance in essential hypertension," N. engl. J. Med. 1987, 217:350-357.
Modan et al, "Hyperinsulinemia--alink between glucose intolerance, obesity, hypertension, dyslipoproteinaemia, elevated serum uric acid and internal kation imbalance," Diab. Met. 1987, 13:375-380.
Skarfors et al, "Do antihypertensive drugs precipitate diabetes in predisposed man?" Br. Med. J. 1989, 298:1147-1152.
Pollare et al, "Insulin Resistance is a Characteristic Feature of Primary Hypertension Independent of Obesity," Metabolism, vol. 39, No. 2 (Feb.), 1990, pp. 167-174.
Pollare et al, "A comparison of the effects of Hydrochlorothiazide and Captopril on Glucose and Lipid metabolism in Patients with Hypertension," New England Journal of Medicine, 321:868-873 (Sep. 28) 1989.
Edelman et al, "Hyperkalemia During Treatment with HMG CoA Reductase Inhibitor," N. Engl. J. Med. (320, No. 18, 1219-20, 1989).
Zorn et al, "Prevention of Arteriosclerotic Lesions with Calcium Antagonists or Captopril in Different Rat Hypertension Models," J. Cardiovasc. Pharmacol. vol. 12 (Suppl. 6), 1988.
Someya et al, "Suppressive Effect of Captopril on Platelet Aggregation in Essential Hypertension," J. Cardiovasc. Pharmacol. 6:840-843, 1984.
Mizuno et al, "The effects of the angiotensin I-converting enzyme inhibitor, captopril, on serum lipoperoxides level and the renin-angiotensin-aldosterone and kallikrein-kinin systems in hypertensive patients," Nippon Naibunpi Gakkai Zasshi, Feb. 20, 1984.
Mizuno et al, "Acute effects of captopril on serum lipid peroxides level in hypertensive patients," Tohoku J. Exp. Med., May, 1984, 143(1) pp. 127-128.
Geisterfer et al, "Angiotensin II Induces Hypertrophy, not Hyperplasia, of of Cultured Rat Aortic Smooth Muscle Cells," Circ. Res. 62:749-756, (1988).
Cecil, Textbook of Medicine, 16 Ed., pp. 239-241. (1983).
McClard et al, "Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate," J.A.C.S. 1987, 109, 5544-5545.
Biller et al, "Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase," Journal of Medicinal Chemistry, 1988, vol. 31, No. 10, pp. 1869-1871.
Lothell et al., "Insulin Sensitivity in Newly Detected Hypertensive Patients", J. Cardiovasc. Pharmacol. 15(Suppl. 5): 546-552, 1990.
Bengtsson et al., "Do antihypertensive drugs precipitate diabetes?", Brit. Med. J., 289:1495-1497, Dec. 1984.
Bergey James L.
Kawano James C.
Tschollar Werner
Yonce Cary S.
E. R. Squibb & Sons Inc.
Jordan Kimberly R.
Rodney Burton
LandOfFree
Method for treating hypertension employing a cholesterol lowerin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating hypertension employing a cholesterol lowerin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating hypertension employing a cholesterol lowerin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886718